Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Pulmonary Embolism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

 



(Medical-NewsWire.com, September 21, 2017 ) Description

“Pulmonary Embolism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Pulmonary Embolism Report is to understand the market and pipeline status of the drugs around the Pulmonary Embolism to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies.

The Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Pulmonary Embolism. While the leading brands, companies and chemicals are considered thoroughly, report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Get a PDF Sample of Report at: http://www.orbisresearch.com/contacts/request-sample/232561 .

SCOPE:

A snapshot of the global Market and Phase III therapeutics scenario for Pulmonary Embolism.
A review of the marketed products under prescription for Pulmonary Embolism, regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Pulmonary Embolism with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Coverage of API Manufacturers for Pulmonary Embolism drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Pulmonary Embolism drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Pulmonary Embolism drugs.
Coverage of Pulmonary Embolism Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure to 2018.
To Browse the Entire Report, Visit : http://www.orbisresearch.com/reports/index/pulmonary-embolism-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2017 .

Reasons to buy

Evaluate the marketing status and exclusivity details of Pulmonary Embolism key products to exploit opportunities for generic drug development opportunities.
Identify and understand important and diverse types of therapeutics under Phase III development for Pulmonary Embolism.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Pulmonary Embolism.
API intelligence over marketed drugs forPulmonary Embolismand gaining primary intelligence over active ingredients manufacturers across the globe.
API intelligence over leading Phase III Pipeline drugs.
Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and
scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Pulmonary Embolism.
Uncovering opportunities in the rapidly growing US market.

No. of Report Pages: 100

Got any Query? Feel free to ask us at : http://www.orbisresearch.com/contacts/enquiry-before-buying/232561 .

Some Points Of TOC:

Indication Overview
Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
Drugs Market Data and Forecasted Sales Figure-2018
Marketed Drugs for Pulmonary Embolism
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
Phase III Drugs for Pulmonary Embolism
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
Discontinued Drugs for Pulmonary Embolism
Appendix
Methodology
Consulting Services
Contact Us
Disclaimer

Orbis Research

Hector Costello

+1 (214) 884-6817

sales@orbisresearch.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC